

Catalog	Unit
TBI5462-5MG	5 mg
TBI5462-25MG	25 mg

### Product Details

**Formal Name:** 1,2-Dihydro-1-[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]-6-[[4-(4-methyl-1-piperazinyl)-phenyl]amino]-2-(2-propen-1-yl)-3H-pyrazolo[3,4-d]pyrimidin-3-one

**Alternate Names:** MK-1775; AZD 1775

**Molecular Formula:** C<sub>27</sub>H<sub>32</sub>N<sub>8</sub>O<sub>2</sub>

**Formula Weight:** 500.60

**CAS Number:** 955365-80-7


**Purity:** >98%

**Formulation:** powder

**Solubility:** Soluble in DMSO (70 mg/ml)

**Storage:** -20°C

**Stability:** ≥ 2 years.



### Applications

Wee1 checkpoint kinase inhibitor

### Functions

Inhibits Wee1 tyrosine kinase (IC<sub>50</sub> = 5.2 nM) thus preventing phosphorylation of CDC2 and abrogating the G<sub>2</sub> DNA damage checkpoint, sensitizing a variety of tumor cells to DNA damaging agents. Adavosertib also blocks Wee1 phosphorylation of E3 ubiquitin ligase SKP2 in human cells, ultimately preventing degradation of CDKs and further allowing cell cycle progression. Stimulates anti-tumor immunity and enhances sensitivity to immune checkpoint blockade by activating ERV and the dsRNA pathway. Potentiates sensitivity of tumors to PARP inhibitors.

### Application Procedures

First dissolved in DMSO (70 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

**For research use only.**